Surgery for gastrointestinal stromal tumour in the post-imatinib era

ANZ Journal of Surgery

Volumn 75, Issue 3, 2005, Pages 165-172

  Neuhaus, Susan J ^a   Clark, Matthew A ^a   Hayes, Andrew J ^a   Thomas, Joseph M ^a   Judson, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

GIST; Imatinib; Surgery

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; IMATINIB;

BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER RELAPSE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES;

EID: 17444392117     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2005.03326.x     Document Type: Review

References (57)

1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231: 51-8.
2. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: a spectrum of disease. Surg. Oncol. 2003; 12: 21-6.
3. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur. J. Cancer 2002; 38: S37-8.
4. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421-3.
5. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347: 472-80.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344: 1052-6.
7. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr. Probl. Surg. 1996; 33: 817-72.
8. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002; 3: 655-64.
9. Kindblom LG, Meis-Kindblom J, Bumminng P, Dimitrijevic S, Miret M, Dortok A, Nilsson B. Incidence, prevalence, phenotype and biological spectrum of gastrointestinal stromal cell tumours (GIST): a population based study of 600 cases. Ann. Oncol. 2002; 13: 157.
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438: 1-12.
11. Ludwig DJ, Traverso LW. Gut stromal tumors and their clinical behavior. Am. J. Surg. 1997; 173: 390-4.
12. Judson I. Gastrointestinal stromal tumours (GIST): biology and treatment. Ann. Oncol. 2002; 13: 287-9.
13. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch. Surg. 2001; 136: 383-9.
14. Burkill GJ, Badran M, Al-Muderis O et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-32.
15. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am. J. Surg. Pathol. 1983; 7: 507-19.
16. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
17. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 1998; 152: 1259-69.
18. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 1998; 11: 728-34.
19. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 2002; 33: 459-65.
20. Nishida T, Hirota S, Taniguchi M et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. 1998; 19: 323-4.
21. Ishida T, Wada I, Horiuchi H, Oka T, Machinami R. Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen's disease). Pathol. Int. 1996; 46: 689-95.
22. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br. J. Surg. 2003; 90: 332-9.
23. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 2000; 60: 3899-903.
24. Komdeur R, Hoekstra HJ, Molenaar WM et al. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. Clin. Cancer Res. 2003; 9: 2926-32.
25. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum. Pathol. 2002; 33: 478-83.
26. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH. Prognostic assessment of gastrointestinal stromal tumor. Am. J. Clin. Oncol. 2003; 26: 221-8.
27. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am. J. Surg. Pathol. 1999; 23: 82-7.
28. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann. Surg. Oncol. 2001; 8: 290-9.
29. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. 1992; 215: 68-77.
30. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88: 66-74.
31. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992; 69: 1334-41.
32. Medeiros FCC, Duensing A, Hornick JL et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004; 28: 889-94.
33. Ahmad K. KIT not the only determinant for GISTs. Lancet Oncol. 2003; 4: 136.
34. Wakai TKT, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br. J. Cancer 2004; 90: 2059-61.
35. Duensing AMF, McConarty B, Joseph NE et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004; 23: 3999-4006.
36. Stroobants S, Goeminne J, Seegers M et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 2003; 39: 2012-20.
37. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21: 4342-9.
38. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
39. Verweij JCP, Zalcberg J, Le Cesne A et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. 2003; 22: 814.
40. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
41. Shen EFAI, Plevris J, Penman ID. Endoscopic ultrasonography in the diagnosis and management of suspected upper gastrointestinal submucosal tumours. Br. J. Surg. 2002; 89: 231-5.
42. Lozano MD, Rodriguez J, Algarra SM, Panizo A, Sola JJ, Pardo J. Fine-needle aspiration cytology and immunocytochemistry in the diagnosis of 24 gastrointestinal stromal tumors: a quick, reliable diagnostic method. Diagn. Cytopathol. 2003; 28: 131-5.
43. Reddy MPRP, Lilien DL. F-18 FDG PET imaging in gastrointestinal stromal tumour. Clin. Nucl. Med. 2003; 28: 677-9.
44. Ghanem N, Altehoefer C, Furtwangler A et al. Computed tomography in gastrointestinal stromal tumors. Eur. Radiol. 2003; 13: 1669-78.
45. Kim CJ, Day S, Yeh KA. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am. Surg. 2001; 67: 135-7.
46. Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982; 49: 177-87.
47. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumours. Surg. Endosc. 2001; 18: 893-5.
48. Rohatgi A, Singh KK. Laparoendoscopic managment of gastrointestinal stromal tumours. J. Laparoendosc. Adv. Surg. Tech. A. 2003; 13: 37-40.
49. Walsh RM, Ponsky J, Brody F, Matthews BD, Heniford BT. Combined endoscopic/laparoscopic intragastric resection of gastric stromal tumors. J. Gastrointest. Surg. 2003; 7: 386-92.
50. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br. J. Surg. 2003; 90: 1178-86.
51. Schneider U, Pink D, Emmerich K, Kettlehack C, Boetschke O, Reichardt P. Resection of progressive or residual tumour after treatment with imatinib for advaned GI stromal tumours. Ann. Surg. Oncol. 2004; 11: S53.
52. Shima Y, Horimi T, Ishikawa T etal. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J. Hepatobil. Pancreat. Surg. 2003; 10: 77-80.
53. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann. Surg. 2001; 234: 540-7; discussion 547-8.
54. Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 2000; 18: 3211-20.
55. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur. J. Cancer 1999; 35: 413-19.
56. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 2002; 33: 466-77.
57. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.